Newsylist real-time news trend intelligence
◼ Archived Business 🔮 Newsylist predicts: still trending tomorrow medium confidence — graded ✗ wrong

Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 June 2026

Eli Lilly shares surge following a CHMP recommendation for Jaypirca's EU approval to treat chronic lymphocytic leukemia.

15sources
18articles
17velocity
+0%since first seen
47d agofirst detected

📍 Where it landed

The CHMP recommended pirtobrutinib for EU approval in CLL across all lines of therapy. Following this, Eli Lilly submitted a marketing authorization application for Jaypirca to the European Commission.

Epilogue added 44d ago, after coverage quieted.

Velocity

How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →

171260Jun 27 19:51Jun 29 11:30 UTC

The brief

The Committee for Medicinal Products for Human Use (CHMP) has recommended pirtobrutinib (Jaypirca) for approval in the European Union. The recommendation covers the treatment of adults with chronic lymphocytic leukemia (CLL) across all lines of therapy.

Coverage from Yahoo Finance, The Pharma Letter, and the European Medicines Agency (EMA) emphasizes the regulatory progress for Jaypirca. Simultaneously, financial outlets such as TIKR.com, Moomoo, and TradingKey report that Eli Lilly stock rose significantly, citing both the EU panel's backing and expanded Medicare access for GLP-1 medications.

Eli Lilly has submitted a marketing authorization application for Jaypirca to the European Commission. Further attention is directed toward the results of the BRUIN CLL-322 trial and the potential for treatment-free remissions.

Synthesized by Newsylist from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 44d ago.

The reporting (18)

Quick answers

What was the CHMP's recommendation for Jaypirca?

The CHMP recommended pirtobrutinib (Jaypirca) for EU approval in adults with chronic lymphocytic leukemia (CLL) across all lines of therapy.

How did Eli Lilly's stock react to the news?

The stock surged, with reports citing gains of 4%, 6.15%, and 7%.

What other factors contributed to Eli Lilly's stock movement?

Investors are also focusing on obesity franchise momentum and the opening of Medicare access for GLP-1 medications.

People, places & organizations

Eli Lilly Meeting U.S Stocks Move Eli Lilly Shares Jump Eli Lilly and Co LLY.US Rises Over Target Means for Investors Medicare Opens GLP-1 Access What Eli Lilly Stock Jumps CHMP Recommends Pirtobrutinib for EU Approval Medicare GLP-1 Access and Obesity Franchise Momentum

Topics

Eli Lilly CHMP Jaypirca Chronic Lymphocytic Leukemia EMA

Related trends